Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Locally Advanced Sarcoma: early-phase trial registry
1 of 3 indexed Locally Advanced Sarcoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Locally Advanced Sarcoma: 3 US clinical trials tracked, 1 recruiting.
Locally Advanced Sarcoma is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Mohammed M Milhem, running 1 of these trials.
Enrollment posture brief
Registry condition locally-advanced-sarcoma
OPEN 1 | RECR 33% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Locally Advanced Sarcoma lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Locally Advanced Sarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Locally Advanced Sarcoma is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
M.D. Anderson Cancer Center
NCT04771520
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
National Cancer Institute (NCI)
NCT04595747
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
Mohammed M Milhem
NCT01106872
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Locally Advanced Sarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Locally Advanced Sarcoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Locally Advanced Sarcoma page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Locally Advanced Sarcoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Mohammed M Milhem sponsors the most Locally Advanced Sarcoma trials on record, review their full trial history before evaluating a specific study. See Mohammed M Milhem's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Locally Advanced Sarcoma condition card totals 3 registered trials; most-linked intervention Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.